Key terms
About NXTC
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NXTC news
Apr 08
11:45am ET
Promising Clinical Outlook for NextCure’s Novel ADC LNCB74 Spurs Buy Rating
Apr 08
7:10am ET
NextCure and LCB present data on B7-H4 antibody drug conjugate at AACR
Apr 04
7:16am ET
NextCure appoints Rakesh Dixit to Scientific Advisory Board
Mar 22
6:17am ET
Promising Clinical Trial Results for NextCure’s NC410 Bolster Buy Rating
Mar 21
2:30pm ET
Analysts Offer Insights on Healthcare Companies: Femasys (FEMY) and NextCure (NXTC)
Mar 21
9:12am ET
NextCure Inc to Engage with Investors in Informal Talks
Mar 21
9:03am ET
NextCure restructures operations, reduces workforce by 37%
Mar 21
9:02am ET
NextCure announces intention to partner assets
Mar 21
9:01am ET
NextCure to prioritize NC410 combo, LNCB74 in 2024
Mar 21
8:56am ET
NextCure expects resources to fund operations into 2H26
Mar 21
8:56am ET
NextCure reports 2023 EPS ($2.25), consensus ($2.28)
Mar 05
6:09pm ET
NextCure’s treatment of AML granted FDA orphan designation
Mar 05
8:26am ET
NextCure publishes preclinical data on function of FLRT3
Jan 22
2:21pm ET
Analysts’ Top Healthcare Picks: Ardelyx (ARDX), Generation Bio (GBIO)
Jan 18
4:18pm ET
NextCure presents preclinical VSTM-1 data
No recent press releases are available for NXTC
NXTC Financials
Key terms
Ad Feedback
NXTC Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NXTC Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range